Our Mission

To discover novel therapeutics that will stop the progression
of neurodegenerative diseases by targeting their underlying causes.

Our Programs

CURRENT CLINICAL TRIALS 
NPT520-34 Phase 1 in Healthy Volunteers
UCB0599 Phase 1b in PD Patients

News

Neuropore Therapies Appoints Dr. Joseph S. McCracken to Board of Directors October 29, 2019

Neuropore Therapies, Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the underlying causes of neurodegenerative disease, announced today the appointment of Joseph S. McCracken, DVM, MS to its board of directors.

See All News

NPT® Publications

Neuropore publishes paper describing the preclinical in vivo characterization of a small molecule compound targeting α-synuclein as a potential Parkinson's disease therapeutic
November 2nd, 2018

Report in Scientific Reports, describes the beneficial effects of NPT200-11 on multiple disease relevant endpoints in a transgenic mouse model of Parkinson's disease.

See All Publications

 

 

A team poised for success

About Our Team

Our Partners




Corporate

UCB Logo


Foundations & Academic InstitutionsSEE ALL

The Michael J. Fox Foundation for Parkinson's Research
Albert Einstein College of Medicine
University of Sydney

Connect with Neuropore